Company: FTII
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001641172-25-011790
Chunk: 46

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Item 8
Chunk 46
---
 Bradford A. Zakes, solely
in the capacity as seller representative.

Pursuant to the Merger Agreement,
the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following the consummation of
the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge with and into LBI Merger
Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing of the Transactions
(the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.” and the Company’s
common stock is expected to list on the NASDAQ Capital Market under the ticker symbol “LBIO.”

The consummation of the proposed Longevity Business
Combination is subject to certain conditions as further described in the Merger Agreement.

In connection with the
execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered into a
Voting and Support Agreement (the “Longevity Support Agreement”) with the Company and Longevity, pursuant to which the Voting Stockholder has agreed
to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by
certain other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to
cause the approval of the Transactions on behalf of Longevity.

In connection with the
execution of the Merger Agreement, the Company, Longevity, the Sponsor have entered into a Voting and Support Agreement (the
“Sponsor Support Agreement”). The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of the
proposed transactions contemplated by the Merger Agreement, (ii) to appear at the purchaser special meeting for purposes of
constituting a quorum, (iii) to vote against any proposals that would materially impede the proposed transactions contemplated by
the Merger Agreement, (iv) to not redeem any shares of the Company’s Common Stock held by it that may be redeemed, and (v) to
waive any adjustment to the conversion ratio set forth in the Company’s amended and restated certificate of incorporation (as
amended from time to time, the “Charter”) with respect to shares of the Class B Common Stock of the Company held by the
Sponsor, in each